MX2023008251A - Mutantes de fimh, composiciones con estos y uso de estos. - Google Patents

Mutantes de fimh, composiciones con estos y uso de estos.

Info

Publication number
MX2023008251A
MX2023008251A MX2023008251A MX2023008251A MX2023008251A MX 2023008251 A MX2023008251 A MX 2023008251A MX 2023008251 A MX2023008251 A MX 2023008251A MX 2023008251 A MX2023008251 A MX 2023008251A MX 2023008251 A MX2023008251 A MX 2023008251A
Authority
MX
Mexico
Prior art keywords
fimh
mutants
polypeptides
compositions therewith
lectin domain
Prior art date
Application number
MX2023008251A
Other languages
English (en)
Spanish (es)
Inventor
Jeroen Geurtsen
Eveline Marleen Weerdenburg
Kellen Cristhina Fae
Jan Grijpstra
Louris Jakob Feitsma
Original Assignee
Janssen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceuticals Inc filed Critical Janssen Pharmaceuticals Inc
Publication of MX2023008251A publication Critical patent/MX2023008251A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MX2023008251A 2021-01-12 2022-01-11 Mutantes de fimh, composiciones con estos y uso de estos. MX2023008251A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21151126 2021-01-12
PCT/IB2022/050166 WO2022153166A1 (en) 2021-01-12 2022-01-11 Fimh mutants, compositions therewith and use thereof

Publications (1)

Publication Number Publication Date
MX2023008251A true MX2023008251A (es) 2023-07-26

Family

ID=74175646

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023008251A MX2023008251A (es) 2021-01-12 2022-01-11 Mutantes de fimh, composiciones con estos y uso de estos.

Country Status (12)

Country Link
US (3) US11725028B2 (cg-RX-API-DMAC7.html)
EP (1) EP4277921A1 (cg-RX-API-DMAC7.html)
JP (2) JP7532672B2 (cg-RX-API-DMAC7.html)
KR (2) KR102746713B1 (cg-RX-API-DMAC7.html)
CN (1) CN116888140A (cg-RX-API-DMAC7.html)
AR (1) AR124604A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022207740B2 (cg-RX-API-DMAC7.html)
CA (1) CA3207841A1 (cg-RX-API-DMAC7.html)
IL (1) IL303954B2 (cg-RX-API-DMAC7.html)
MX (1) MX2023008251A (cg-RX-API-DMAC7.html)
TW (1) TW202241929A (cg-RX-API-DMAC7.html)
WO (1) WO2022153166A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY209568A (en) 2020-01-16 2025-07-22 Janssen Pharmaceuticals Inc Fimh mutant, compositions therewith and use thereof
CN116888140A (zh) 2021-01-12 2023-10-13 杨森制药公司 FimH突变体、其组合物及其用途
EP4448002A1 (en) * 2021-12-17 2024-10-23 Pfizer Inc. Polynucleotide compositions and uses thereof

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4987237A (en) 1983-08-26 1991-01-22 Ribi Immunochem Research, Inc. Derivatives of monophosphoryl lipid A
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
JPH0655749B2 (ja) 1989-09-20 1994-07-27 日本たばこ産業株式会社 リピッドa単糖類縁体
US5370872A (en) 1991-08-12 1994-12-06 Swiss Serum And Vaccine Institute Berne Escherichia coliO-polysaccharide-protein conjugate vaccine
US5593969A (en) 1991-09-03 1997-01-14 Igen Incorporated Lipid-A analogs: monosaccharide and dissaccharide compounds for inhibiting binding of lipid A receptors to lipid A receptors
DE69313134T2 (de) 1992-06-25 1998-02-26 Smithkline Beecham Biolog Adjuvantien enthaltende impfstoffzusammensetzung
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
AU743114B2 (en) 1997-04-01 2002-01-17 Corixa Corporation Aqueous immunologic adjuvant compositions of monophosphoryl lipid A
US6491919B2 (en) 1997-04-01 2002-12-10 Corixa Corporation Aqueous immunologic adjuvant compostions of monophosphoryl lipid A
US6500434B1 (en) 1998-04-23 2002-12-31 Medimmune, Inc. Chaperone and adhesin proteins; vaccines, diagnostics and method for treating infections
US6858211B1 (en) 1998-07-20 2005-02-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccines against Escherichia coli O157 infection
ES2284287T3 (es) 1998-10-16 2007-11-01 Glaxosmithkline Biologicals S.A. Sistemas adyuvantes y vacunas.
JP2003505030A (ja) * 1999-07-15 2003-02-12 メディミューン,インコーポレーテッド FimHアドヘジンベイストワクチン
US6759241B1 (en) 1999-10-04 2004-07-06 University Of Maryland Biotechnology Institute Adjuvant comprising a lipopolysaccharide antagonist
WO2001078777A2 (en) 2000-04-13 2001-10-25 Mossman, Sally Immunostimulant compositions comprising an aminoalkyl glucosaminide phosphate and qs-21
AU2001271907A1 (en) 2000-07-07 2002-01-21 Medimmune, Inc. FimH adhesin proteins and methods of use
EP1313502A4 (en) * 2000-08-18 2005-10-19 Medimmune Inc ADMINISTRATIVE PROCEDURE OF FIMH PROTEIN AS A VACCINE AGAINST HARNWAY INFECTIONS
WO2002102974A2 (en) * 2000-12-08 2002-12-27 Medimmune, Inc. Mutant proteins, high potency inhibitory antibodies and fimch crystal structure
US6676958B2 (en) 2001-06-19 2004-01-13 Advanced Bioadjuvants, Llc Adjuvant composition for mucosal and injection delivered vaccines
CN101019123A (zh) * 2004-02-06 2007-08-15 科学与工业研究委员会 用于识别有治疗潜力的粘附素和粘附素样蛋白的计算方法
CN101355928B (zh) 2005-04-26 2013-05-22 卫材R&D管理株式会社 用于癌症免疫疗法的组合物和方法
ES2535084T3 (es) 2005-05-11 2015-05-05 Eth Zurich Proteínas N-glicosiladas recombinantes procedentes de células procariotas
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
ATE539079T1 (de) 2006-03-23 2012-01-15 Novartis Ag Imidazochinoxalinverbindungen als immunmodulatoren
CA2646891A1 (en) 2006-03-23 2007-09-27 Novartis Ag Immunopotentiating compounds
SI2257307T1 (sl) 2008-02-20 2018-09-28 Glaxosmithkline Biologicals S.A. Biokonjugati, izdelani iz rekombinantnih N-glikoziliranih proteinov iz prokariontskih celic
CA2764374C (en) 2009-06-05 2019-11-19 Infectious Disease Research Institute Synthetic glucopyranosyl lipid adjuvants
PL2811981T3 (pl) 2012-02-07 2019-09-30 Infectious Disease Research Institute Ulepszone formulacje adiuwantowe zawierające agonistę TLR4 oraz sposoby ich zastosowania
CU24377B1 (es) 2013-05-18 2018-12-05 Aduro Biotech Inc Dinucléotidos de purina cíclicos y composiciones de los mismos útiles para inducir la producción de interferón de tipo i dependientes de sting
US9415101B2 (en) 2013-09-25 2016-08-16 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US20150086592A1 (en) 2013-09-25 2015-03-26 Sequoia Sciences, Inc Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9149521B2 (en) 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9415097B2 (en) 2013-09-25 2016-08-16 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9149522B2 (en) 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9504743B2 (en) 2013-09-25 2016-11-29 Sequoia Sciences, Inc Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
NZ723328A (en) 2014-02-24 2018-01-26 Glycovaxyn Ag Compositions comprising e. coli o25b antigen, uses thereof and methods of manufacture
US10722580B2 (en) * 2015-05-13 2020-07-28 University Of Washington Compositions and methods for treatment and prevention of uropathogenic E. coli infection
CN107847580B (zh) 2015-07-07 2022-08-12 扬森疫苗与预防公司 针对rsv的疫苗
TWI715617B (zh) 2015-08-24 2021-01-11 比利時商葛蘭素史密斯克藍生物品公司 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物
WO2019048871A1 (en) * 2017-09-08 2019-03-14 The University Of Bristol PROTEIN ADMINISTRATION TO MEMBRANES
TW201946650A (zh) * 2018-03-12 2019-12-16 美商詹森藥物公司 針對腹內感染之疫苗
WO2021123360A1 (en) * 2019-12-20 2021-06-24 Vib Vzw Nanobody exchange chromatography
MY209568A (en) 2020-01-16 2025-07-22 Janssen Pharmaceuticals Inc Fimh mutant, compositions therewith and use thereof
CN116888140A (zh) 2021-01-12 2023-10-13 杨森制药公司 FimH突变体、其组合物及其用途

Also Published As

Publication number Publication date
CA3207841A1 (en) 2022-07-21
US11725028B2 (en) 2023-08-15
US20230406890A1 (en) 2023-12-21
JP7532672B2 (ja) 2024-08-13
EP4277921A1 (en) 2023-11-22
AR124604A1 (es) 2023-04-12
CN116888140A (zh) 2023-10-13
US20220220159A1 (en) 2022-07-14
JP2024109576A (ja) 2024-08-14
IL303954B2 (en) 2025-04-01
IL303954A (en) 2023-08-01
KR102746713B1 (ko) 2024-12-24
JP2024502854A (ja) 2024-01-23
AU2022207740A1 (en) 2023-06-29
US20250289854A1 (en) 2025-09-18
KR20230125842A (ko) 2023-08-29
KR20250007029A (ko) 2025-01-13
AU2022207740B2 (en) 2024-06-06
TW202241929A (zh) 2022-11-01
WO2022153166A1 (en) 2022-07-21
US12297238B2 (en) 2025-05-13
IL303954B1 (en) 2024-12-01
AU2022207740A9 (en) 2024-09-05

Similar Documents

Publication Publication Date Title
AR121066A1 (es) Mutante de fimh, composiciones que lo contienen y uso del mismo
CL2017000201A1 (es) Composiciones y métodos de uso para tratar trastornos metabólicos
AR124604A1 (es) Mutantes de fimh, composiciones con los mismos y uso de los mismos
MY166228A (en) Compositions comprising mixtures of semifluorinated alkanes
NZ770137A (en) Lactobacillus gasseri kbl697 strain and use thereof
MX2018013622A (es) Agentes agonistas de cd47 que inducen muerte celular programada y su uso en los tratamientos de enfermedades asociadas con defectos en la muerte celular programada.
BR112018017031A2 (pt) formulações de antagonista de il-6 e usos das mesmas
MX2022008663A (es) Composiciones alergenicas mixtas y metodos de uso de las mismas.
MX2017014082A (es) Nuevas proteinas especificas para cd137.
BR112017017949A2 (pt) regimes de iniciação-reforço envolvendo administração de pelo menos um constructo de mrna
SA521421715B1 (ar) تركيبات سيماجلوتيد ثابتة واستخداماتها
BR112019017393A2 (pt) formulações de evolocumab de baixa viscosidade, alta concentração e métodos para produzir as mesmas
BR112016024352A2 (pt) ?cepa de listeria recombinante, listeria recombinante, composição farmacêutica, e, métodos de induzir uma resposta imune contra um tumor ou um câncer em um indivíduo humano e de listeria?
BR112021015751A2 (pt) Vetores de terapia genética para tratamento da doença de danon
BR112018010937A2 (pt) composições de anticorpos enxertados com citocina e métodos de uso para imunorregulação
CO2023013465A2 (es) Composiciones y métodos para inhibir cetohexoquinasa (khk)
BR112018016912A2 (pt) novo antígeno para uso na vacina contra malária
BR112019008349A2 (pt) composição de peptídeos, e, utilização de uma composição.
PE20151978A1 (es) Composiciones nutricionales que contienen un componente peptidico con propiedades antinflamatorias y usos del mismo
MX2020009733A (es) Composiciones.
BR112018067946A2 (pt) formulações tópicas contendo ciclosporina e usos das mesmas
MA45172B1 (fr) Arn modifié codant pour des polypeptides vegf-a, formulations et utilisations associées
ZA202107825B (en) Pharmaceutical parenteral composition of dual glp1/2 agonist
MX2020007760A (es) Composiciones y metodos para mejorar la biodisponibilidad de 5-hidroxitriptofano.
MX2020005223A (es) Método para aumentar la tasa de implantación embrionaria en una paciente que padece síndrome de ovario poliquístico.